MediWound (NASDAQ:MDWD) Upgraded to Sell by StockNews.com

StockNews.com upgraded shares of MediWound (NASDAQ:MDWD) to a sell rating in a report published on Wednesday.

Separately, HC Wainwright reiterated a buy rating and issued a $28.00 price objective on shares of MediWound in a research report on Thursday, May 30th.

MediWound Stock Down 6.7 %

Shares of NASDAQ:MDWD opened at $14.51 on Wednesday. The company has a market cap of $134.71 million, a price-to-earnings ratio of -10.51 and a beta of 0.81. The business has a 50 day moving average price of $16.64 and a 200 day moving average price of $14.73. MediWound has a twelve month low of $7.10 and a twelve month high of $19.86.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings data on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.01. The company had revenue of $4.96 million during the quarter, compared to analysts’ expectations of $4.65 million. MediWound had a negative return on equity of 21.67% and a negative net margin of 64.24%. Analysts anticipate that MediWound will post -1.93 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of MediWound during the 4th quarter worth about $803,000. Sargent Investment Group LLC grew its stake in MediWound by 7.0% during the fourth quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock worth $1,111,000 after buying an additional 7,125 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. increased its holdings in shares of MediWound by 45.7% during the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock worth $1,276,000 after buying an additional 39,348 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of MediWound in the first quarter valued at approximately $427,000. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of MediWound by 241.6% in the 1st quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after acquiring an additional 93,705 shares in the last quarter. 46.83% of the stock is owned by institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.